comparemela.com

Latest Breaking News On - Nasdaq akro - Page 3 : comparemela.com

Akero Therapeutics (NASDAQ:AKRO) Posts Earnings Results, Misses Estimates By $0 01 EPS

Akero Therapeutics (NASDAQ:AKRO – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.01), MarketWatch Earnings reports. Akero Therapeutics Trading Up 5.0 % Akero Therapeutics stock opened at $14.91 on Wednesday. The company has a debt-to-equity ratio […]

Akero Therapeutics (NASDAQ:AKRO) Releases Quarterly Earnings Results, Misses Expectations By $0 01 EPS

Akero Therapeutics (NASDAQ:AKRO – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.01), MarketWatch Earnings reports. Akero Therapeutics Stock Performance AKRO stock opened at $14.91 on Wednesday. The firm has a market cap of $829.00 million, […]

Akero Therapeutics (NASDAQ:AKRO) Posts Earnings Results, Misses Expectations By $0 01 EPS

Akero Therapeutics (NASDAQ:AKRO – Get Free Report) released its earnings results on Monday. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.01), MarketWatch Earnings reports. Akero Therapeutics Trading Up 5.0 % NASDAQ:AKRO opened at $14.91 on Wednesday. Akero Therapeutics has a 52-week low of $11.25 […]

Akero Therapeutics (NASDAQ:AKRO) Price Target Cut to $39 00 by Analysts at Cantor Fitzgerald

Akero Therapeutics (NASDAQ:AKRO – Free Report) had its target price decreased by Cantor Fitzgerald from $69.00 to $39.00 in a research report released on Wednesday, Benzinga reports. Cantor Fitzgerald currently has an overweight rating on the stock. AKRO has been the subject of several other reports. Evercore ISI cut their price objective on shares of […]

Morgan Stanley Trims Akero Therapeutics (NASDAQ:AKRO) Target Price to $33 00

Akero Therapeutics (NASDAQ:AKRO – Free Report) had its price objective lowered by Morgan Stanley from $70.00 to $33.00 in a research report released on Wednesday morning, Benzinga reports. The firm currently has an overweight rating on the stock. A number of other research analysts also recently issued reports on AKRO. UBS Group assumed coverage on […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.